Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Clare Mudd"'
Autor:
Claire J Cairney, Lauren S Godwin, Alan E Bilsland, Sharon Burns, Katrina H Stevenson, Lynn McGarry, John Revie, Jon D Moore, Ceri M Wiggins, Rebecca S Collinson, Clare Mudd, Elpida Tsonou, Mahito Sadaie, Dorothy C Bennett, Masashi Narita, Christopher J Torrance, W Nicol Keith
Publikováno v:
PLoS Genetics, Vol 13, Iss 8, p e1006942 (2017)
Senescence is a universal barrier to immortalisation and tumorigenesis. As such, interest in the use of senescence-induction in a therapeutic context has been gaining momentum in the past few years; however, senescence and immortalisation remain unde
Externí odkaz:
https://doaj.org/article/9c37fdc4728e4b2584673b3d2d9b5b8b
Autor:
Edward Coulstock, Jane Sosabowski, Milan Ovečka, Rob Prince, Laura Goodall, Clare Mudd, Armin Sepp, Marie Davies, Julie Foster, Jerome Burnet, Gráinne Dunlevy, Adam Walker
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57263 (2013)
Interferon alpha (IFNα) is used for the treatment of hepatitis C infection and whilst efficacious it is associated with multiple adverse events including reduced leukocyte, erythrocyte, and platelet counts, fatigue, and depression. These events are
Externí odkaz:
https://doaj.org/article/2bf102b9d60e482eb3241a465d3d6f8f
Autor:
Clare Mudd, Ross J. Maxwell, Emma J. Haagensen, Ceri M. Wiggins, Huw D. Thomas, Elpida Tsonou, Jonathan D. Moore, David R. Newell
Publikováno v:
European Journal of Cancer. 56:69-76
Studies to identify predictive biomarkers can be carried out in isogenic cancer cell lines, which enable interrogation of the effect of a specific mutation. We assessed the effects of four drugs, the PI3K-mammalian target of rapamycin inhibitor dacto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc92cfdca53c940ad350c3a7262b0877
https://doi.org/10.1016/j.ejca.2015.12.012
https://doi.org/10.1016/j.ejca.2015.12.012
Publikováno v:
Cancer Research. 73:4289-4289
Advances in the development of clinically effective therapeutic strategies for targeting KRAS mutant tumors have been hampered by the lack of suitable in vitro tools and the inability to correlate findings from current in vitro KRAS dependency models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::011195211fc182c75b33046c57f99ab3
https://doi.org/10.1158/1538-7445.am2013-4289
https://doi.org/10.1158/1538-7445.am2013-4289